Suppr超能文献

专家多学科瓣膜团队评估后二尖瓣反流管理的结果

Outcomes of Mitral Valve Regurgitation Management after Expert Multidisciplinary Valve Team Evaluation.

作者信息

Welman Myrthe J M, Streukens Sebastian A F, Mephtah Anass, Hoebers Loes P, Vainer Jindrich, Theunissen Ralph, Heuts Samuel, Maessen Jos G, Segers Patrique, Vernooy Kevin, van 't Hof Arnoud W J, Sardari Nia Peyman, Vriesendorp Pieter A

机构信息

Department of Cardiology, Maastricht University Medical Centre+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.

Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.

出版信息

J Clin Med. 2024 Jul 31;13(15):4487. doi: 10.3390/jcm13154487.

Abstract

: Mitral regurgitation (MR) affects millions worldwide, necessitating timely intervention. There are significant clinical challenges in the conservative management of MR, leaving a knowledge gap regarding the impact of multidisciplinary decision-making on treatment outcomes. This study aimed to provide insights into the impact of multidisciplinary decision-making on the survival outcomes of MR patients, focusing on conservative approaches. : This study retrospectively analyzes 1365 patients evaluated by an expert multidisciplinary heart team (MDT) in a single center from 2015 to 2022. Treatments included surgery, catheter-based interventions, and conservative management. Propensity matching was utilized to compare surgery and conservative approaches. : Surgical intervention was associated with superior long-term survival outcomes compared to conservative and catheter-based treatments, particularly for degenerative MR (DMR). Survival rates of patients deemed by the MDT to have non-severe DMR were comparable to surgical patients (HR 1.07, 95% CI: 0.37-3.12, = 0.90). However, non-severe functional MR (FMR) patients trended towards elevated mortality risk (HR 1.77, 95% CI: 0.94-3.31, = 0.07). Pharmacological treatment for DMR was associated with significantly higher mortality compared to surgery (HR 8.0, 95% CI: 1.78-36.03, = 0.001). Functional MR patients treated pharmacologically exhibited a non-significantly higher mortality risk compared to surgical intervention (HR 1.93, 95% CI: 0.77-4.77, = 0.20). : Survival analysis revealed significant benefits for surgical intervention, contrasting with elevated mortality risks associated with conservative management. "Watchful waiting" may be appropriate for non-severe DMR, while FMR may require closer monitoring. Further research is needed to assess the impact of regular follow-up or delayed surgery on survival rates, as pharmacological therapy has limited long-term efficacy for DMR.

摘要

二尖瓣反流(MR)在全球影响着数百万人,需要及时干预。二尖瓣反流的保守治疗存在重大临床挑战,在多学科决策对治疗结果的影响方面存在知识空白。本研究旨在深入了解多学科决策对二尖瓣反流患者生存结果的影响,重点关注保守治疗方法。

本研究回顾性分析了2015年至2022年在单一中心由专家多学科心脏团队(MDT)评估的1365例患者。治疗方法包括手术、基于导管的干预措施和保守治疗。采用倾向匹配法比较手术和保守治疗方法。

与保守治疗和基于导管的治疗相比,手术干预具有更好的长期生存结果,尤其是对于退行性二尖瓣反流(DMR)。MDT认为非严重DMR患者的生存率与手术患者相当(风险比[HR]1.07,95%置信区间[CI]:0.37 - 3.12,P = 0.90)。然而,非严重功能性二尖瓣反流(FMR)患者的死亡风险有上升趋势(HR 1.77,95% CI:0.94 - 3.31,P = 0.07)。与手术相比,DMR的药物治疗与显著更高的死亡率相关(HR 8.0,95% CI:1.78 - 36.03,P = 0.001)。接受药物治疗的功能性二尖瓣反流患者与手术干预相比,死亡风险虽无显著升高,但有上升趋势(HR 1.93,95% CI:0.77 - 4.77,P = 0.20)。

生存分析显示手术干预有显著益处,这与保守治疗相关的较高死亡风险形成对比。“密切观察等待”可能适用于非严重DMR患者,而FMR患者可能需要更密切的监测。由于药物治疗对DMR的长期疗效有限,需要进一步研究以评估定期随访或延迟手术对生存率的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b832/11313528/7fba199fb381/jcm-13-04487-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验